NCT05487599: An ongoing trial by Prevail Therapeutics
This trial is ongoing. It must report results 6 years, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05487599 |
|---|---|
| Title | An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 20, 2022 |
| Completion date | Nov. 30, 2031 |
| Required reporting date | Nov. 29, 2032, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |